Cas:95080-43-6 2-Amino-3-(1,3-benzodioxol-5-yl)-2-methylpropanamide manufacturer & supplier

Chemical Name:2-Amino-3-(1,3-benzodioxol-5-yl)-2-methylpropanamide

CAS.NO:95080-43-6

Synonyms:2-Amino-3-(1,3-benzodioxol-5-yl)-2-methylpropanamide

Molecular Formula:C₁₁H₁₄N₂O₃

Molecular Weight:222.24000

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:88.56000

Exact Mass:222.10000

LogP:2.01050

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 2-Amino-3-(1,3-benzodioxol-5-yl)-2-methylpropanamide chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-Amino-3-(1,3-benzodioxol-5-yl)-2-methylpropanamide physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-Amino-3-(1,3-benzodioxol-5-yl)-2-methylpropanamide Use and application,2-Amino-3-(1,3-benzodioxol-5-yl)-2-methylpropanamide technical grade,usp/ep/jp grade.

Related News: In order to find answers to these questions, our staff in the development department set about conducting a series of experiments. 2-Amino-3-(1,3-benzodioxol-5-yl)-2-methylpropanamide manufacturer All of China��s provinces and territories have now been touched by the outbreak. 2-Amino-3-(1,3-benzodioxol-5-yl)-2-methylpropanamide supplier As part of the agreement, ICIG will enter into a 5-year supply contract to provide Genzyme with materials needed for the production of eliglustat tartrate, an investigational treatment for Gaucher disease Type 1 that is currently in Phase III clinical trials. 2-Amino-3-(1,3-benzodioxol-5-yl)-2-methylpropanamide vendor In order to find answers to these questions, our staff in the development department set about conducting a series of experiments. 2-Amino-3-(1,3-benzodioxol-5-yl)-2-methylpropanamide factory As part of the agreement, ICIG will enter into a 5-year supply contract to provide Genzyme with materials needed for the production of eliglustat tartrate, an investigational treatment for Gaucher disease Type 1 that is currently in Phase III clinical trials.